Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 13/20 | 0.53 |
| ▸ | SCN1A | P35498 | 2/20 | 0.51 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.51 |
| ▸ | GPR139 | Q6DWJ6 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL318179 | 0.89 | SCN5A (0.55) | SCN5ASCN1ASCN2AGPR139 | |
| SCHEMBL252292 | 0.88 | SCN5A (0.58) | SCN5ASCN1ASCN2AGPR139 | |
| SCHEMBL253168 | 0.85 | SCN5A (0.57) | SCN5ASCN1ASCN2AGPR139 | |
| SCHEMBL252649 | 0.84 | SCN5A (0.58) | SCN5ASCN1ASCN2AGPR139 | |
| SCHEMBL318666 | 0.84 | SCN5A (0.54) | SCN5ASCN1ASCN2AGPR139KDM4E | |
| SCHEMBL252156 | 0.83 | SCN5A (0.57) | SCN5ASCN1ASCN2AGPR139 | |
| SCHEMBL253071 | 0.83 | SCN5A (0.57) | SCN5ASCN1ASCN2AGPR139 | |
| SCHEMBL251915 | 0.83 | SCN5A (0.62) | SCN5ASCN1ASCN2AGPR139 | |
| SCHEMBL317247 | 0.83 | SCN5A (0.57) | SCN5ASCN1ASCN2AGPR139 | |
| SCHEMBL251310 | 0.83 | SCN5A (0.59) | SCN5ASCN1ASCN2AGPR139 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9079901-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20150080370-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2015-03-19 | — | — | US | disclosed |
| US-8703759-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| EP-2588197-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | Gilead Sciences, Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20120010192-A1 | Fused Heterocyclic Compounds as Ion Channel Modulators | GILEAD SCIENCES, INC. | 2012-01-12 | — | — | US | disclosed |
| WO-2012003392-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080370-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, KCNH2, CACNA1E | SCN5A 37/4885SCN1A 43/4885SCN2A 55/4885 |
| US-20120010192-A1 | Fused Heterocyclic Compounds as Ion Channel Modulators | KCNJ2, KCNH2, CACNA1E | SCN5A 37/4885SCN1A 43/4885SCN2A 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.